ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 954,48
1,85%
DAX
18 518,03
-0,44%
Brent Oil
83,315
-1,22%
Bitcoin
65 216,86
0,55%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
26/05/201918h39Dow Jones NewsTeva Settles Oklahoma Opioid Case for $85 MillionNYSE:TEVATeva Pharmaceutical Industries Ltd
26/05/201916h30Business WireCompany Statement: Teva Reaches Agreement with State of Oklahoma to Resolve State’s Claims Against the CompanyNYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/201917h51Business WireTeva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/201923h31Dow Jones NewsTeva Launches Generic Version of Tarceva in USNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/201922h06Business WireTeva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/201914h00Business WireTeva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/201913h00Business WireTeva Reports First Quarter 2019 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
01/05/201921h01Business WireTeva Announces Launch of a Generic Version of Letairis® (ambrisentan) Tablets in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
01/05/201914h00Business WireTeva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy of NeurologyNYSE:TEVATeva Pharmaceutical Industries Ltd
01/05/201902h28Dow Jones NewsWhistleblower Challenges SEC Over Delay on Award DecisionNYSE:TEVATeva Pharmaceutical Industries Ltd
23/04/201917h10Dow Jones NewsTeva Ends Development of Fremanezumab in Cluster HeadacheNYSE:TEVATeva Pharmaceutical Industries Ltd
23/04/201915h00Business WireTeva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster HeadacheNYSE:TEVATeva Pharmaceutical Industries Ltd
22/04/201917h03Business WireTeva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/201918h07Dow Jones NewsTeva Pharma Gets FDA Approval to Market Generic Nasal Spray for Opioid OverdosesNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/201916h00Business WireTeva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
10/04/201914h00Business WireTeva Signs New $2.3 Billion Syndicated Revolving Credit FacilityNYSE:TEVATeva Pharmaceutical Industries Ltd
08/04/201923h00Business WireTeva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019NYSE:TEVATeva Pharmaceutical Industries Ltd
05/04/201918h25Dow Jones NewsOklahoma Attorney General Dismisses Some Claims Against Opioid Makers -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
05/04/201914h44Dow Jones NewsOklahoma Attorney General Dismisses Some Claims Against Opioid MakersNYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/201914h08Business WireTeva’s AJOVY® Receives EU Approval Offering Patients the First & Only Anti-CGRP Treatment with Both Quarterly & Monthly Do...NYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/201909h00Business WireTeva’s COPAXONE® 40mg – Favorable Response from European Patent OfficeNYSE:TEVATeva Pharmaceutical Industries Ltd
25/03/201923h14Dow Jones NewsOklahoma Court Refuses to Delay Opioid Trial -- ReutersNYSE:TEVATeva Pharmaceutical Industries Ltd
22/03/201920h43Business WireTeva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/03/201914h25GlobeNewswire Inc.Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activi...NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/201922h08Business WireTeva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/201902h50Dow Jones NewsTeva, FTC Reach Tentative Settlement in Low-Cost Generics Lawsuits -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/201901h47Dow Jones NewsTeva, FTC Reach Tentative Settlement in Low-Cost Generics LawsuitsNYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/201900h24Business WireTeva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the PartiesNYSE:TEVATeva Pharmaceutical Industries Ltd
19/02/201914h39Edgar (US Regulatory)Annual Report (10-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
19/02/201913h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BIT
O8JPA5
MORGAN STANLEY BV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés